Literature DB >> 6775342

Entry of diazepam and its major matabolite into cerebrospinal fluid.

D J Greenblatt, H R Ochs, B L Lloyd.   

Abstract

Five dogs received a single 1.0 mg/kg dose of diazepam (DZ) IV. Concentrations of DZ and its major metabolite desmethyldiazepam (DMDZ) were simultaneously measured in plasma and cisternal cerebrospinal fluid (CSF) for up to 8 h after the dose by electron-capture gas-liquid chromatography. DZ was rapidly eliminated from plasma (half-life 0.3--1.3 h); DZ disappearance was mirrored by formation of DMDZ, which in turn was eliminated slowly, Both DZ and DMDZ rapidly penetrated CSF and concentrations in CSF declined parallel with those in plasma. Despite rapid uptake, the extent of CSF transfer of DZ and DMDZ was limited by plasma protein binding. Mean CSF:plasma concentrtion ratios for DZ (range 0.023--0.137) and DMDZ (range 0.047--0.119) were highly correlated with the unbound fraction in plasma (r = 0.95 and 0.80, respectively). Thus DZ and DMDZ concentrations in CSF, presumed to reflect concentrations at the site of action, are determined by unbound plasma concentrations. The intensity of pharmacologic action is more likely to correlate with unbound than with total plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6775342     DOI: 10.1007/bf00432376

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  Anticonvulsant level in saliva, serum, and cerebrospinal fluid.

Authors:  A S Troupin; P Friel
Journal:  Epilepsia       Date:  1975-06       Impact factor: 5.864

2.  Simultaneous gas-chromatographic analysis for diazepam and its major metabolite, desmethyldiazepam, with use of double internal standardization.

Authors:  D J Greenblatt
Journal:  Clin Chem       Date:  1978-10       Impact factor: 8.327

3.  Pharmacokinetic and clinical implications of quinidine protein binding.

Authors:  E Woo; D J Greenblatt
Journal:  J Pharm Sci       Date:  1979-04       Impact factor: 3.534

4.  Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid.

Authors:  L Lund; A Berlin; K M Lunde
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

5.  Pharmacokinetics of diazepam in dogs, mice and humans.

Authors:  E van der Klejin; J M van Rossum; E T Muskens; N V Rijntjes
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971

6.  Brain uptake of phenytoin, phenobarbital, and diazepam.

Authors:  R E Ramsay; E J Hammond; R J Perchalski; B J Wilder
Journal:  Arch Neurol       Date:  1979-09

7.  Plasma and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients.

Authors:  D R Stanski; D J Greenblatt; A Selwyn; R I Shader; K Franke; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

Review 8.  Clinical pharmacokinetics of diazepam.

Authors:  M Mandelli; G Tognoni; S Garattini
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

9.  Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat.

Authors:  U Klotz; K H Antonin; P R Bieck
Journal:  J Pharmacol Exp Ther       Date:  1976-10       Impact factor: 4.030

10.  Cerebrospinal-fluid concentrations of nitrazepam in man.

Authors:  L Kangas; J Kanto; T Siirtola; A Pekkarinen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-07
View more
  21 in total

Review 1.  Relationships between CSF drug concentrations, receptor binding characteristics, and pharmacokinetic and pharmacodynamic properties of selected 1,4-substituted benzodiazepines.

Authors:  W A Colburn; M L Jack
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

2.  Relationship between drug plasma concentrations and psychomotor performance after single doses of ethanol and benzodiazepines.

Authors:  J Ingum; R Bjørklund; A Bjørneboe; A S Christophersen; E Dahlin; J Mørland
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Distribution of diazepam, nordiazepam, and oxazepam between brain extraneuronal space, brain tissue, plasma, and cerebrospinal fluid in diazepam and nordiazepam dependent dogs.

Authors:  E P Wala; W R Martin; J W Sloan
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Comparative absorption kinetics of intramuscular midazolam and diazepam.

Authors:  O R Hung; J B Dyck; J Varvel; S L Shafer; D R Stanski
Journal:  Can J Anaesth       Date:  1996-05       Impact factor: 5.063

5.  Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation.

Authors:  R K Dubey; C B McAllister; M Inoue; G R Wilkinson
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

6.  Subjective and behavioral effects of diazepam depend on its rate of onset.

Authors:  H de Wit; S Dudish; J Ambre
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Benzodiazepine pharmacodynamics: utility of eye movement measures.

Authors:  P P Roy-Byrne; D S Cowley; A Radant; D Hommer; D J Greenblatt
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam.

Authors:  E H Ellinwood; D G Heatherly; A M Nikaido; T D Bjornsson; C Kilts
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium.

Authors:  H R Ochs; E Steinhaus; A Locniskar; M Knüchel; D J Greenblatt
Journal:  Klin Wochenschr       Date:  1982-04-15

10.  Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate.

Authors:  R I Shader; D J Greenblatt; D A Ciraulo; M Divoll; J S Harmatz; A Georgotas
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.